Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2009 1
2010 1
2011 2
2012 1
2013 2
2015 3
2016 4
2017 1
2018 1
2019 3
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, Lænkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG). Acs B, et al. Among authors: zabaglo la. Mod Pathol. 2022 Oct;35(10):1362-1369. doi: 10.1038/s41379-022-01104-9. Epub 2022 Jun 21. Mod Pathol. 2022. PMID: 35729220 Free PMC article.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, Vidya R, Skene A, Dodson A, Hills M, Detre S, Zabaglo L, Banerji J, Kilburn L, Morden JP, Robertson JFR, Smith I, Dowsett M; POETIC Trialists. Bliss JM, et al. Among authors: zabaglo l. Breast Cancer Res. 2023 Apr 12;25(1):39. doi: 10.1186/s13058-023-01626-3. Breast Cancer Res. 2023. PMID: 37046348 Free PMC article. Clinical Trial.
Predictive algorithms for adjuvant therapy: TransATAC.
Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J. Dowsett M, et al. Among authors: zabaglo l. Steroids. 2011 Jul;76(8):777-80. doi: 10.1016/j.steroids.2011.02.032. Epub 2011 Apr 4. Steroids. 2011. PMID: 21470560
An international Ki67 reproducibility study.
Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. Polley MY, et al. Among authors: zabaglo la. J Natl Cancer Inst. 2013 Dec 18;105(24):1897-906. doi: 10.1093/jnci/djt306. Epub 2013 Nov 7. J Natl Cancer Inst. 2013. PMID: 24203987 Free PMC article.
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer.
Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, Trahearn N, Hrebien S, Garcia-Murillas I, Chkhaidze K, Ermini L, Huntingford IS, Cottom H, Zabaglo L, Koelble K, Khalique S, Rusby JE, Muscara F, Dowsett M, Maley CC, Natrajan R, Yuan Y, Schiavon G, Turner N, Sottoriva A. Barry P, et al. Among authors: zabaglo l. Clin Cancer Res. 2018 Oct 1;24(19):4763-4770. doi: 10.1158/1078-0432.CCR-17-3374. Epub 2018 Jun 11. Clin Cancer Res. 2018. PMID: 29891724 Free PMC article.
An international study to increase concordance in Ki67 scoring.
Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Lænkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO. Polley MY, et al. Among authors: zabaglo la. Mod Pathol. 2015 Jun;28(6):778-86. doi: 10.1038/modpathol.2015.38. Epub 2015 Feb 20. Mod Pathol. 2015. PMID: 25698062 Free article.
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Pancholi S, Leal MF, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, Zabaglo L, Hills M, Dodson A, Gao Q, Johnston SR, Dowsett M, Cosulich SC, Maragoni E, Martin LA. Pancholi S, et al. Among authors: zabaglo l. Breast Cancer Res. 2019 Dec 4;21(1):135. doi: 10.1186/s13058-019-1222-0. Breast Cancer Res. 2019. PMID: 31801615 Free PMC article.
25 results